FDA Turns Down F2G’s Antifungal, But Firm Plots Comeback As Trial Completes Accrual
The US regulatory agency asked for more data and analyses for olorofim, which F2G hopes to provide from an ongoing Phase IIb study.
The US regulatory agency asked for more data and analyses for olorofim, which F2G hopes to provide from an ongoing Phase IIb study.